MMJ Files Pre Investigational New Drug (IND) Application With FDA For Pharmaceutical THC -CBD derived medicine.

MMJ Files FDA application to initiate clinical trials assessing the company’s cannabinoid pharmaceutical compounds for treating and/or preventing symptoms associated with multiple sclerosis (MS) has been filed.

MMJ International Holding’s, the premier medical cannabis research company that is advancing the science of medical marijuana through patient clinical research and the operation of medical cannabis healthcare businesses, announced today MMJ ‘s filing of an Investigational New Drug (IND) application with the FDA to initiate clinical trials assessing the company’s cannabinoid pharmaceutical compounds for treating and/or preventing symptoms associated with multiple sclerosis (MS).

Dr. Bianca Weinstock-Guttman is a Professor of Neurology who serves as Executive Director of the New York State Multiple Sclerosis Consortium will execute the FDA approved study exploring the potential therapeutic applications of cannabinoids for progressive multiple sclerosis patients. MMJ’s will be providing new evidence regarding clinical outcomes leading to commercial success in the scientific process of MMJ ‘s first pharmaceutical THC-CBD derived medicine.

MMJ’s first clinical trial of cannabis-based medicines involving patients suffering from Multiple Sclerosis and its related forms of severe pain and spasticity will be seeking FDA permission to proceed to undertake a pharmaceutical research study to develop a prescription cannabis-based medicine. MMJ will commence their Phase 2 clinical trials with the guidance of their clinical research organization.

Timothy Moynahan Chairman MMJ  stated, “We are very excited about the FDA’s acceptance of our pre IND request, “MMJ’s discovery of a novel cannabinoid pharmacology through our network of world leading scientists and regulatory expertise uniquely position us to develop and manufacture plant-derived cannabinoid formulations at sufficient quality and uniformity according to the FDA regulatory requirements for pharmaceutical development.”

Mr. Moynahan added, “Our initiation of the Phase 2 clinical trial programs and the eventual FDA Fast Track Designation for Progressive Multiple Sclerosis signify important steps forward in MMJ ‘s ongoing commitment to investigating innovative scientific approaches with the hope of bringing new treatment options to MS patients.